New therapeutic horizons in chronic kidney disease: the role of SGLT2 inhibitors in clinical practice.
Author
Evans, MarcMorgan, Angharad R
Whyte, Martin B
Hanif, Wasim
Bain, Stephen C
Kalra, Philip A
Davies, Sarah
Dashora, Umesh
Yousef, Zaheer
Patel, Dipesh C
Strain, W David
Publication date
2021-12-21
Metadata
Show full item recordAbstract
Chronic kidney disease (CKD) is a serious, progressive condition associated with significant patient morbidity. Hypertension control and use of renin-angiotensin system blockers are the cornerstones of treatment for CKD. However, even with these treatment strategies, many individuals will progress towards kidney failure. Recently, sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical trials with primary renal endpoints have firmly established SGLT2 inhibition, in addition to standard of care, as an effective strategy to slow down the progression of CKD and reduce some of its associated complications. The emergence of this new clinical evidence supports the use of SGLT2 inhibitors in the management of CKD in people with and without diabetes. As licensing and guidelines for SGLT2 inhibitors are updated, there is a need to adapt CKD treatment pathways and for this class of drugs to be included as part of standard care for CKD management. In this article, we have used consensus opinion alongside the available evidence to provide support for the healthcare community involved in CKD management, regarding the role of SGLT2 inhibitors in clinical practice. By highlighting appropriate prescribing and practical considerations, we aim to encourage greater and safe use of SGLT2 inhibitors for people with CKD, both with and without diabetes.Citation
Evans M, Morgan AR, Whyte MB, Hanif W, Bain SC, Kalra PA, Davies S, Dashora U, Yousef Z, Patel DC, Strain WD. New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs. 2022 Feb;82(2):97-108. doi: 10.1007/s40265-021-01655-2. Epub 2021 Dec 21Type
ArticleAdditional Links
https://link.springer.com/journal/40265PMID
34932209Journal
DrugsPublisher
Springer Internationalae974a485f413a2113503eed53cd6c53
10.1007/s40265-021-01655-2